DE121067T1 - Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin. - Google Patents

Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin.

Info

Publication number
DE121067T1
DE121067T1 DE198484101701T DE84101701T DE121067T1 DE 121067 T1 DE121067 T1 DE 121067T1 DE 198484101701 T DE198484101701 T DE 198484101701T DE 84101701 T DE84101701 T DE 84101701T DE 121067 T1 DE121067 T1 DE 121067T1
Authority
DE
Germany
Prior art keywords
heparin
mol
oligosaccharide fractions
pharmacological properties
hydrogen peroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198484101701T
Other languages
English (en)
Inventor
Pietro I-41040 Corlo Bianchini (Mo)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE121067T1 publication Critical patent/DE121067T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Claims (3)

  1. Übersetzung der Patentansprüche nach Art. 67, 3
    Verfahren zur Herstellung von Oligosaccharidfraktionen, die mit pharmakologischen Eigenschaften versehen sind, mittels Heparinabbaues ,
    dadurch gekennzeichnet, daß eine wässrige Heparinlösung, die zwischen 5 und 20 g Heparin pro Liter enthält, in Gegenwart von 4-5Om. mol/Liter Askorbinsäure,von 0,4 - 2,5 m.mol/1 Kupferazetat und von 50 - 300 m.mol/1 Wasserstoffperoxid bei einer Temperatur zwischen 40 und 50 C für 20 - 24 Stunden einer Inkubation unterzogen wird, wobei der pH-Wert durch Kupferazetat zwischen 7,5 und 0 gehalten wird.
  2. 2. Verfahren nach Anspruch 1,
    dadurch gekennzeichn
    e t
    daß
    das Verfahren bei einem pH-Wert von 7,0 durchgeführt wird,
  3. 3. Verfahren nach Anspruch 1,
    dadurch gekennzeichnet, daß • die wässrige Heparinlösung 10g/l Heparin, 20 m.mol/1 Askorbinsäure, 2,25 m.mol Kupferazetat und 180 m.mol/1 Wasserstoffperoxid enthält und daß das Verfahren bei einer Temperatur von 50 C für 24 Stunden bei einem
    pH-Wert von 7,8 durch Natriumazetat durchgeführt wird,
    Oligosaccharidfraktionen von Heparin, die durch ein Verfahren nach den vorstehenden Ansprüchen erhalten werden.
DE198484101701T 1983-03-08 1984-02-18 Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin. Pending DE121067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT40021/83A IT1195497B (it) 1983-03-08 1983-03-08 Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina

Publications (1)

Publication Number Publication Date
DE121067T1 true DE121067T1 (de) 1985-01-17

Family

ID=11246670

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198484101701T Pending DE121067T1 (de) 1983-03-08 1984-02-18 Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin.
DE8484101701T Expired DE3463386D1 (en) 1983-03-08 1984-02-18 Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8484101701T Expired DE3463386D1 (en) 1983-03-08 1984-02-18 Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin

Country Status (9)

Country Link
US (3) US4629699A (de)
EP (1) EP0121067B1 (de)
JP (1) JPS59187002A (de)
AT (1) ATE26843T1 (de)
AU (1) AU549885B2 (de)
CA (1) CA1212942A (de)
DE (2) DE121067T1 (de)
IT (1) IT1195497B (de)
ZA (1) ZA841520B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1163772B (it) * 1983-07-13 1987-04-08 Baldacci Lab Spa Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1208509B (it) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
EP0337327A1 (de) * 1988-04-09 1989-10-18 Bioiberica, S.A. Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5519010A (en) * 1989-02-06 1996-05-21 Taiho Pharmaceutical Co., Ltd. Sulfated polysaccharide, pharmaceutically acceptable salt thereof, process for preparing same and medicament containing same as effective component
WO1991015217A1 (en) * 1990-04-06 1991-10-17 Washington University Anticoagulant oligosaccharides
IT1243987B (it) * 1990-10-29 1994-06-28 Derivati Organici Lab Procedimento per la preparazione di epossi-eparidi prodotti ottenuti ecomposizioni farmaceutiche che li contengono
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
GB9206291D0 (en) * 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
EP0669827B1 (de) * 1992-11-10 2001-05-23 Yeda Research And Development Co. Ltd. Zusammensetzungen für die regulation der cytokinaktivität
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
BR9713141A (pt) * 1996-11-27 2000-02-08 Rhone Poulenc Rorer Pharma Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
CA2293595A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
US6235725B1 (en) 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
EP1192187A1 (de) * 1999-06-30 2002-04-03 Hamilton Civic Hospitals Research Development, Inc. Heparinzusammensetzungen, die gerinnselzugehörige gerinnungsfakoren verhindert
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
CZ2003961A3 (cs) * 2000-09-08 2003-10-15 Hamilton Civic Hospitals Research Development, Inc. Farmaceutický prostředek k inhibici nebo prevenci tvorby či aktivity thrombinu
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
EP1582531A1 (de) 2004-03-24 2005-10-05 Aventis Pharma S.A. Verfahren zur Oxydierung nicht-fraktionierten Heparins und die Detektion der Anwesenheit oder Abwesenheit von Glykoserin in Heparin und in von Heparin abgeleiteten Produkten
ITMI20042068A1 (it) * 2004-10-29 2005-01-29 Opocrin Spa Nuovo uso di eparine a bassissimo peso molecolare
ATE552004T1 (de) 2005-11-30 2012-04-15 Istituto G Ronzoni Oral verabreichbare heparinderivate
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (de) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Nicht gerinnungshemmende polysaccharidzusammensetzungen
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
US8186278B2 (en) * 2008-08-04 2012-05-29 Industrial Design Fabrication & Installation, Inc. Gear switch for a conveyor assembly
EP2526122B1 (de) 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Beurteilung von heparinzubereitungen
WO2011130697A2 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
CN106947004A (zh) * 2017-03-02 2017-07-14 浙江大学 一种低分子量肝素的制备方法
CN107090052A (zh) * 2017-05-16 2017-08-25 浙江大学 一种低分子量果胶的制备方法
CN110809474A (zh) * 2017-06-20 2020-02-18 加利福尼亚大学董事会 生物活性寡糖的生产
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
WO2021007429A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1083903B (it) * 1977-08-09 1985-05-25 Lobo Srl Oligo-eteropolisaccaridi con attivita' eparinosimili,procedimento per il loro ottenimento e relative composizioni terapeutiche
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
JPS56120704A (en) * 1980-01-28 1981-09-22 Hepar Ind Inc Method of obtaining low molecular weight heparin having heightened pharmacologic property* product manufactured thereby and its use
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance

Also Published As

Publication number Publication date
DE3463386D1 (en) 1987-06-04
IT8340021A1 (it) 1984-09-08
IT8340021A0 (it) 1983-03-08
AU2509384A (en) 1984-09-13
IT1195497B (it) 1988-10-19
US4933326A (en) 1990-06-12
EP0121067B1 (de) 1987-04-29
JPS59187002A (ja) 1984-10-24
EP0121067A1 (de) 1984-10-10
CA1212942A (en) 1986-10-21
ATE26843T1 (de) 1987-05-15
JPS6344765B2 (de) 1988-09-06
ZA841520B (en) 1984-10-31
AU549885B2 (en) 1986-02-20
US4629699A (en) 1986-12-16
US4791195A (en) 1988-12-13

Similar Documents

Publication Publication Date Title
DE121067T1 (de) Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin.
DE3102621C2 (de)
US2767167A (en) Process of reducing the viscosity of gums
ATE17562T1 (de) Verfahren zur herstellung von kupfer-ii-hydroxid.
DE3854245D1 (de) Verfahren zur Herstellung von Chinolinen.
DE2207287C3 (de) Verfahren zur Herstellung von Biscarboxyäthyl-germaniumsesquioxid
CH486487A (de) Verfahren zur Herstellung von disubstituierten Adenosinderivaten
DE59102161D1 (de) Verfahren zur Herstellung von 3-Methylpyrazol.
ATE56940T1 (de) Verfahren zur herstellung von 2,2,4-trimethyl-1,3-pentandiolmonoisobutyrat.
KR870004706A (ko) 글로빈 또는 아세틸 글로빈의 철-유도체의 제조방법
EP0120182B1 (de) Verfahren zur Gewinnung von D,L-Homocystin
DE2709500C2 (de) Verfahren zur Reinigung von Heparin
DE1112293B (de) Verfahren zur Herstellung von Polymilchsaeure
ATE33496T1 (de) Verfahren zur herstellung von organischen oligosacchariden uebereinstimmend mit fragmenten von natuerlichen muco-polysacchariden, die erhaltenen oligosaccharide und ihre biologische verwendung.
DE574841C (de) Verfahren zur Darstellung von esterartigen hochmolekularen Umwandlungsprodukten des Caseins
DE565177C (de) Verfahren zur Herstellung saurer Wollfarbstoffe der Anthrachinonreihe
DE835925C (de) Verfahren zur Herstellung pyrogenfreier Heparinpraeparate
DE954592C (de) Verfahren zur Gewinnung von koagulationshindernden Mitteln
DE510437C (de) Verfahren zur Darstellung von Benzimidazolonstibinsaeuren
AT228222B (de) Verfahren zur Herstellung von neuen 4,4'-disubstituierten Diphenylsulfonen
AT275053B (de) Verfahren zur Herstellung von neuen, basischen Additionssalzen von Ribonucleinsäure
DE1954519A1 (de) Verfahren zum Herstellen von 0-Acylthiamindisulfiden
DE963507C (de) Verfahren zur Herstellung von Polyschwefelsaeureestern des Chitosans
JPS57102205A (en) Dialysis membrane made of regenerated cellulose of cuprammonium process and its production
ATE24715T1 (de) Cycloaliphatische aminosulfonsaeurederivate, verfahren zu deren herstellung und arzneimittel zur bekaempfung von herz- und gefaesskrankheiten.